Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
ID: 357165Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357165

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-072.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)," aimed at accelerating the development of evidence-based cancer interventions that address health disparities among diverse populations in the United States. This initiative will support research that tests the impact of cancer-related interventions on outcomes through a pragmatic trial design, structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and government entities, with funding amounts capped at $500,000 for the UG3 phase and $750,000 for the UH3 phase. Interested parties should note that applications are due by November 17, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-072-Full-Announcement.html
    PAR-25-072.html
    The National Cancer Institute (NCI) under the Department of Health and Human Services has issued a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)." This initiative is designed to accelerate the development of evidence-based cancer interventions, focusing on diverse populations and settings across the United States. The funding will support research testing the impact of cancer-related interventions on outcomes through a pragmatic trial design. The program is structured in two phases: the UG3 phase for preparatory activities and intervention refinement, followed by the UH3 phase for conducting the trial. Eligible applicants include higher education institutions, nonprofits, and government entities, with awards capped at $500,000 for UG3 and $750,000 for UH3 phases. Applications must address health disparities and demonstrate collaboration with key stakeholders. This funding opportunity underscores the government's commitment to enhancing cancer care through rigorous testing in real-world contexts, ultimately aiming to improve public health outcomes for underserved populations.
    Similar Opportunities
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Natural Products for Cancer Interception and Prevention" under the cooperative agreement mechanism. This initiative aims to support innovative projects that focus on the discovery and development of novel natural products that are safe, nontoxic, and effective in intercepting or preventing cancer, with a structured approach divided into two phases: the UG3 phase for initial target selection and assay validation, followed by the UH3 phase for large-scale evaluations and pharmacokinetic assessments. The total funding available for this program is $4.5 million over the fiscal years 2024 to 2026, with a deadline for applications set for June 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.